We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
Read MoreHide Full Article
Shares of TG Therapeutics, Inc. (TGTX - Free Report) have rallied 29.5% in the past three months against the industry’s decline of 11.2%.
The company’s sole marketed drug Briumvi (ublituximab-xiiy) was approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) in December 2022. Sales of the drug exceeded management’s expectations in 2024.
The company’s top line primarily comprises product sales from Briumvi and royalty and other revenues.
Briumvi has been witnessing strong adoption from patients in recent quarters and the trend is likely to continue in 2025. Net product sales of Briumvi were $313.7 million in 2024 compared with $92 million recorded in 2023.
The better-than-expected sales performance of Briumvi can be attributed as the reason for the stock’s increase during the said time.
Image Source: Zacks Investment Research
TGTX's Key Developments Related to Briumvi
TG Therapeutics expects to record worldwide revenues of around $540 million in 2025, including net product revenues of almost $525 million from Briumvi sales in the United States.
The company has obtained three additional patents from the United States Patent and Trademark Office (USPTO) for Briumvi, which extended the drug’s patent protection through 2042. This should protect Briumvi sales from generic erosion in the United States.
TG Therapeutics is developing a self-administered subcutaneous formulation of Briumvi for treating patients with RMS. Last August, the company initiated a phase I study evaluating subcutaneous Briumvi in patients with RMS.
It is also conducting a phase I study evaluating subcutaneous Briumvi in patients with myasthenia gravis.
TGTX's Other Pipeline Studies
TG Therapeutics entered into a licensing agreement with Precision BioSciences, Inc. (DTIL - Free Report) to acquire global rights to DTIL’s allogeneic CD19 CAR T therapy, azercabtagene zapreleucel (azer-cel), for the treatment of certain autoimmune disorders in January 2024.
The FDA cleared the investigational new drug application (IND) for azer-cel for the treatment of progressive forms of multiple sclerosis (MS) in August 2024.
Enrollment of participants in the phase I study on azer-cel in progressive MS is expected to begin shortly.
The strong adoption for Briumvi, along with an encouraging pipeline progress, should continue drive TGTX stock in 2025.
In the past 60 days, estimates for Jazz Pharmaceuticals’ earnings per share have increased from $22.11 to $23.33 for 2025. During the same time, earnings per share estimates for 2026 increased from $23.23 to $23.35. Year to date, shares of JAZZ have declined 10.6%.
JAZZ’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.20%.
In the past 60 days, estimates for Krystal Biotech’s earnings per share have increased from $5.40 to $7.00 for 2025. During the same time, earnings per share estimates for 2026 increased from $9.15 to $10.84. Year to date, shares of KRYS have rallied 7.4%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.29%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why
Shares of TG Therapeutics, Inc. (TGTX - Free Report) have rallied 29.5% in the past three months against the industry’s decline of 11.2%.
The company’s sole marketed drug Briumvi (ublituximab-xiiy) was approved by the FDA for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) in December 2022. Sales of the drug exceeded management’s expectations in 2024.
The company’s top line primarily comprises product sales from Briumvi and royalty and other revenues.
Briumvi has been witnessing strong adoption from patients in recent quarters and the trend is likely to continue in 2025. Net product sales of Briumvi were $313.7 million in 2024 compared with $92 million recorded in 2023.
The better-than-expected sales performance of Briumvi can be attributed as the reason for the stock’s increase during the said time.
Image Source: Zacks Investment Research
TGTX's Key Developments Related to Briumvi
TG Therapeutics expects to record worldwide revenues of around $540 million in 2025, including net product revenues of almost $525 million from Briumvi sales in the United States.
The company has obtained three additional patents from the United States Patent and Trademark Office (USPTO) for Briumvi, which extended the drug’s patent protection through 2042. This should protect Briumvi sales from generic erosion in the United States.
TG Therapeutics is developing a self-administered subcutaneous formulation of Briumvi for treating patients with RMS. Last August, the company initiated a phase I study evaluating subcutaneous Briumvi in patients with RMS.
It is also conducting a phase I study evaluating subcutaneous Briumvi in patients with myasthenia gravis.
TGTX's Other Pipeline Studies
TG Therapeutics entered into a licensing agreement with Precision BioSciences, Inc. (DTIL - Free Report) to acquire global rights to DTIL’s allogeneic CD19 CAR T therapy, azercabtagene zapreleucel (azer-cel), for the treatment of certain autoimmune disorders in January 2024.
The FDA cleared the investigational new drug application (IND) for azer-cel for the treatment of progressive forms of multiple sclerosis (MS) in August 2024.
Enrollment of participants in the phase I study on azer-cel in progressive MS is expected to begin shortly.
The strong adoption for Briumvi, along with an encouraging pipeline progress, should continue drive TGTX stock in 2025.
TG Therapeutics, Inc. Price
TG Therapeutics, Inc. price | TG Therapeutics, Inc. Quote
TGTX's Zacks Rank & Stocks to Consider
TG Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Jazz Pharmaceuticals, Inc. (JAZZ - Free Report) and Krystal Biotech, Inc. (KRYS - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Jazz Pharmaceuticals’ earnings per share have increased from $22.11 to $23.33 for 2025. During the same time, earnings per share estimates for 2026 increased from $23.23 to $23.35. Year to date, shares of JAZZ have declined 10.6%.
JAZZ’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.20%.
In the past 60 days, estimates for Krystal Biotech’s earnings per share have increased from $5.40 to $7.00 for 2025. During the same time, earnings per share estimates for 2026 increased from $9.15 to $10.84. Year to date, shares of KRYS have rallied 7.4%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.29%.